Attackers don't need any special authentication to reach a target endpoint — they just need to know where it is.

Ongoing research into AI agent framework security identified an exploit chain in AutoGen Studio (AutoGen’s open-source prototyping user interface) that allows untrusted web content rendered by a ...

Washington — The House on Tuesday passed Republicans' $70 billion bill funding immigration enforcement agencies through the rest of President Trump's term, bringing an end to the monthslong stalemate ...

Sometimes, to solve a particular system architecture problem, you have to invent a new technology. And sometimes, you just need to squint at the problem a little and look at what you already have and ...

FDA tested over 300 samples from 16 brands Majority of samples had very low levels of contaminants Secretary Kennedy to host industry roundtable on infant formula safety in May April 29 (Reuters) - ...

The numbers are the first to quantify the effect of the Trump administration’s shutdown and restarting of a program that has saved millions of lives worldwide. By Apoorva Mandavilli The United ...

The case of a Utah teenager murdered more than 50 years ago is finally closed after authorities said Wednesday that DNA evidence confirmed she was a victim of notorious serial killer Ted Bundy.

Google API keys for services like Maps embedded in accessible client-side code could be used to authenticate to the Gemini AI assistant and access private data. Researchers found nearly 3,000 such ...

A protein lurking around in the blood can help with the accurate diagnosis of Alzheimer's disease. In a recent study, researchers from Spain investigated how blood-based biomarkers, such as a protein ...

Grail said it “plans to extend the trial's follow up period by 6-12 months” in order to look “for a stronger effect with longer follow up as data matures.” (Getty Images) Grail’s shares plummeted more ...

Grail, a healthcare company seeking to help more patients detect cancer early while it can still be cured, has had a difficult five years, facing job cuts, restructuring, and a botched acquisition.

The stock slid 47%, to $54.20, in after-hours trading. Through market close, share have surged 93% in the past year. The healthcare company said Thursday the test failed to meet the trial's target of ...